Access to anti-retroviral drugs, male in Philippines

Philippines: Access to anti-retroviral drugs, male was 42.0% in 2024. ◆ Volatile

Latest (2024)
42.0%
Change on year
up 2.4%
World rank
128th
of 141 countries
All-time high
43.0%
in 2022
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Philippines, 2000–2024

0102030402000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 1 %2006: 2 %2007: 3 %2008: 3 %2009: 4 %2010: 5 %2011: 6 %2012: 8 %2013: 14 %2014: 18 %2015: 23 %2016: 28 %2017: 33 %2018: 38 %2019: 42 %2020: 40 %2021: 41 %2022: 43 %2023: 41 %2024: 42 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Philippines stood at 42.0%.

That represents a change of up 2.4% on the previous year and up 133.3% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Philippines peaked at 43.0% in 2022 and was at its lowest, 0.0%, in 2000.

Philippines ranks 128th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Philippines, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Philippines, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 1.0%
2006 2.0% +100.0%
2007 3.0% +50.0%
2008 3.0% +0.0%
2009 4.0% +33.3%
2010 5.0% +25.0%
2011 6.0% +20.0%
2012 8.0% +33.3%
2013 14.0% +75.0%
2014 18.0% +28.6%
2015 23.0% +27.8%
2016 28.0% +21.7%
2017 33.0% +17.9%
2018 38.0% +15.2%
2019 42.0% +10.5%
2020 40.0% -4.8%
2021 41.0% +2.5%
2022 43.0% +4.9%
2023 41.0% -4.7%
2024 42.0% +2.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 1.3% 0.0% 4.0% 10
2010s 21.5% 5.0% 42.0% 10
2020s 41.4% 40.0% 43.0% 5

Countries ranked near Philippines

  1. 125 Bangladesh 45.0% compare
  2. 126 Egypt 44.0% compare
  3. 126 Indonesia 44.0% compare
  4. 128 Mongolia 42.0% compare
  5. 130 Suriname 41.0% compare
  6. 131 Congo 40.0% compare
  7. 131 Ghana 40.0% compare

See the full ranking of 160 places →

More gender data for Philippines

All data for Philippines →

Frequently asked questions

What is access to anti-retroviral drugs, male in Philippines?
Access to anti-retroviral drugs, male in Philippines was 42.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Philippines?
The highest recorded value was 43.0% in 2022.
What is the lowest access to anti-retroviral drugs, male recorded in Philippines?
The lowest recorded value was 0.0% in 2000.
How does Philippines rank for access to anti-retroviral drugs, male?
Philippines ranks 128th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Philippines?
Over the last ten years it is up 133.3%. The long-run trend across the full record is volatile.
Where does this Philippines data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Philippines. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/philippines/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/philippines/">Access to anti-retroviral drugs, male in Philippines</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.